Praxis Precision Medicines provided an update on its portfolio at its 2023 R&D Day. The company reported positive preliminary results from PRAX-222 Part 1, with a 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients. The Phase 3 program for ulixacaltamide is set to begin this quarter, with nearly 600 patients expressing interest in participating. Praxis expects to submit a New Drug Application for ulixacaltamide in 2025. The company also shared additional data from the Phase 1 study of PRAX-628, reinforcing its potential as a next-generation precision anti-seizure medication.